A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
about
FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistanceBenserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2.Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration.The RAS-Effector Interface: Isoform-Specific Differences in the Effector Binding RegionsModeling of RAS complexes supports roles in cancer for less studied partners.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?Drugging the 'undruggable' cancer targets.Turning the tide in myelodysplastic/myeloproliferative neoplasms.Defeat mutant KRAS with synthetic lethality.Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.Latest Advances Towards Ras Inhibition: A Medicinal Chemistry Perspective.Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.The RAS-Effector Interaction as a Drug Target.A New View of Pathway-Driven Drug Resistance in Tumor Proliferation.Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer.Non-kinase targets of protein kinase inhibitors.Drugging RAS: Know the enemy.RAS Proteins and Their Regulators in Human Disease.Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia.Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange.BRSK2 induced by nutrient deprivation promotes Akt activity in pancreatic cancer via downregulation of mTOR activity.Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer.Inhibition of the Ras/Raf interaction and repression of renal cancer xenografts in vivo by an enantiomeric iridium(iii) metal-based compound.Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis.ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines.Arresting kinase suppressor of Ras in an inactive state.Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent.Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells.Posttranslational Modifications of RAS Proteins.The rocky road to personalized medicine in acute myeloid leukaemia.Recent advances in the biology and therapy of medullary thyroid carcinoma.CRISPR Approaches to Small Molecule Target Identification.A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics.Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option.RAS GTPases are modified by SUMOylation.Inhibition of Ras/Raf/MEK/ERK Pathway Signaling by a Stress-Induced Phospho-Regulatory Circuit.Phosphorylation of Rap1 by cAMP-dependent Protein Kinase (PKA) Creates a Binding Site for KSR to Sustain ERK Activation by cAMP.Anticancer drugs: RAS mimetic revealed.
P2860
Q28077347-B867B6C2-D658-44D6-8285-E26C35FF2301Q33587154-E7BB5DF3-296B-4F74-A966-5D65F36AF446Q33701979-C6602F98-8C40-4E24-A05C-A006CEA25365Q36217950-D2DD1646-DB5A-4AE7-A4B5-733670072A8CQ38641385-BB1F7903-6A41-4A6E-A3AD-78D6C052CECEQ38664735-7FB17B1F-185E-4F3C-ADA1-E79A6A5947C3Q38667658-04DA6CF2-FC3E-4569-9678-18C1361EC689Q38712988-2BB7A6C4-9BE9-497C-80A9-F7E570E154E9Q38837319-258998A7-017F-4C6D-89B4-7C0E4BEC0219Q38891257-ABB3067E-3FC3-49EF-8838-C7B42FECD550Q38892507-3AA03CD4-4168-4F8D-9D88-78BB3C8A5BA9Q38956084-F6A1361A-AF10-436B-AB4F-2969D7085C6BQ38961023-DE8142CF-8043-4CAD-B8CD-D4894B1098CEQ39071250-8BB79DEA-89D7-4E5B-8656-A9D201657329Q39155018-EEEC6DE0-EDC4-4FD5-8DA2-2B8D7BE4481EQ39163561-A9A00950-1759-4E46-967B-511276B1BEC0Q39171961-D0A9DBD0-8A58-469E-A325-BB85AD55554AQ39182842-092AAA2D-125B-46DF-9799-AC43801B130FQ39407402-BD0E5955-E37E-4A9A-B7E7-6EAAEC4E0708Q40328357-5AD2D770-D312-4EA6-B694-CC18F787D0B1Q41077398-AE5AADCC-0370-43A3-88D7-97FAC7D31C23Q41280277-22CDF3B9-37CC-458C-BF2C-20EA2036C78EQ41616075-EB155113-855A-488C-8B85-400631D5BEC8Q41671042-8DDF25F2-DA4F-4C65-AA6B-16753FB08625Q41775168-9859787D-472B-4C19-880B-B38611F03E17Q42144794-42DB0779-B1E2-40CA-9CC8-C177B12EDDF1Q42332071-4AEED9A4-B64B-415B-B647-E6CD4A8A6629Q42377052-3A8268B0-03FE-4CFA-94CC-2F2A9D16F9EEQ47155582-9F90949F-7FDD-4C40-BA6F-5EB2E37E3200Q47223139-FC8DA994-EA7D-43C3-AF35-EC3FDF8AE646Q47561008-1D00F8BB-488F-477B-86DA-529373081243Q48246978-17FB395C-24A0-4C7F-8ADD-963E4A4276D8Q48376848-6CEA4828-5C23-4F47-AA94-7D6935B5F3B8Q48711405-79AEB5B6-3343-4630-9DA7-F35918FEAA9FQ49167162-FCB96D24-50FB-4492-880A-A904EF1E9FE6Q49402953-075D4305-1412-4C42-9C5E-CB256BFC1117Q50053066-A6779FB5-0DCE-47E5-B326-BD8DF84B045AQ50075745-A59F3446-6107-41FC-8068-3A2577570373Q51243825-91C4B6F3-58B8-4D30-9482-1C6101B9F5E4Q51728222-477D8367-ECD9-4B10-A03B-8DFB8BF7D80B
P2860
A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A Small Molecule RAS-Mimetic D ...... or Proteins to Block Signaling
@en
A Small Molecule RAS-Mimetic D ...... r Proteins to Block Signaling.
@nl
type
label
A Small Molecule RAS-Mimetic D ...... or Proteins to Block Signaling
@en
A Small Molecule RAS-Mimetic D ...... r Proteins to Block Signaling.
@nl
prefLabel
A Small Molecule RAS-Mimetic D ...... or Proteins to Block Signaling
@en
A Small Molecule RAS-Mimetic D ...... r Proteins to Block Signaling.
@nl
P2093
P2860
P50
P1433
P1476
A Small Molecule RAS-Mimetic D ...... or Proteins to Block Signaling
@en
P2093
Aneel K Aggarwal
Chandan Guha
David Mulholland
E Premkumar Reddy
Indranil Basu
Kaushik Dutta
M V Ramana Reddy
Rodrigo Vasquez-Del Carpio
Sai Krishna Athuluri-Divakar
P2860
P304
P356
10.1016/J.CELL.2016.03.045
P407
P577
2016-04-01T00:00:00Z